Raising Expectations
Building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases because patients and caregivers deserve better.
Overcoming Barriers
Delivering safe, efficacious drugs to the central nervous system (CNS) remains one of the greatest challenges in medicine. This is driven by the blood-brain barrier (BBB), which restricts the entry of large molecules into the CNS, preventing many potential therapeutics from reaching their intended targets.
In partnership with Paragon Therapeutics, Korsana has developed Therapeutic Targeting (THETA™), a novel BBB-penetrant shuttle platform designed to enhance CNS exposure of investigational therapies and overcome limitations of earlier shuttle technologies.
Using THETA, Korsana is advancing precision-engineered therapeutics designed to reduce the burden of some of medicine’s biggest challenges, starting with Alzheimer’s disease.
Learn more about the burden and difficulties of treating Alzheimer’s disease, and our potential best-in-class therapeutic approach.
Latest News
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in…
Korsana Biosciences Strengthens Leadership with Executive and Board Appointments to Support Next Phase of Growth
Matthew Leoni, M.D., appointed Chief Medical Officer and Gan Wei, Ph.D., appointed Chief Technical Officer Heidi Henson appointed to Board…
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases Korsana’s lead…